Biosimilars
FDA-approved highly-similar versions of reference biologics. Plans frequently require biosimilar use first — patient may appeal when continuing on reference biologic is medically necessary.
What this class is
Biosimilars are FDA-approved biologics that are 'highly similar' to a reference biologic with no clinically meaningful differences in safety, purity, and potency. Major biosimilar categories include adalimumab (Humira) biosimilars, infliximab (Remicade) biosimilars, etanercept (Enbrel) biosimilars, rituximab (Rituxan) biosimilars, trastuzumab (Herceptin) biosimilars, bevacizumab (Avastin) biosimilars, and others. The FDA can designate a biosimilar as 'interchangeable', allowing pharmacy substitution without prescriber notification (varies by state).
Representative drugs
- Adalimumab biosimilars (Amjevita, Cyltezo, Hyrimoz, Yusimry, Hadlima, Idacio, Yuflyma, Simlandi, Adalimumab-ryvk)
- Infliximab biosimilars (Inflectra, Renflexis, Avsola, Ixifi)
- Trastuzumab biosimilars (Kanjinti, Trazimera, Ogivri, Ontruzant, Herzuma)
- Bevacizumab biosimilars (Mvasi, Zirabev, Alymsys)
- Rituximab biosimilars (Truxima, Ruxience, Riabni)
Common denial patterns
- Plan requires biosimilar use vs reference biologic
- Plan switches patient from reference to biosimilar mid-treatment
- Stability concern — patient stable on reference, switch could destabilize
- Step therapy requiring biosimilar trial first
Clinical guidelines that win appeals
- FDA Purple Book
- AAOI Position Statement on Biosimilar Substitution
Frequently asked questions
What is biosimilars?
Biosimilars are FDA-approved biologics that are 'highly similar' to a reference biologic with no clinically meaningful differences in safety, purity, and potency. Major biosimilar categories include adalimumab (Humira) biosimilars, infliximab (Remicade) biosimilars, etanercept (Enbrel) biosimilars, rituximab (Rituxan) biosimilars, trastuzumab (Herceptin) biosimilars, bevacizumab (Avastin) biosimilars, and others. The FDA can designate a biosimilar as 'interchangeable', allowing pharmacy substitution without prescriber notification (varies by state).
What are the common denial patterns?
Plan requires biosimilar use vs reference biologic; Plan switches patient from reference to biosimilar mid-treatment; Stability concern — patient stable on reference, switch could destabilize; Step therapy requiring biosimilar trial first.
Which clinical guidelines support appeals?
FDA Purple Book; AAOI Position Statement on Biosimilar Substitution.
Related
- Specialty biologicsHumira, Enbrel, Stelara, Skyrizi, Cosentyx, Rinvoq, Dupixent
- Antifibrotic agentsPirfenidone (Esbriet), nintedanib (Ofev) for idiopathic pulmonary fibrosis (IPF) and progressive pul
- Biologic drugs (mAbs and biosimilars)Monoclonal antibodies and other biologics targeting specific immune or growth pathways. Used in rheu
- Direct oral anticoagulants (DOACs)Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa). Replaced warfar
- GLP-1 receptor agonistsSemaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Sax
Sources
Appeal a biosimilars denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com